GLP-1 Therapies
16 articles on GLP-1 Therapies, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1 Supply Chain: How Shaily & Divi's Impact Drug Access
Two Indian firms are quietly powering the global GLP-1 weight loss boom. Learn how their manufacturing roles affect drug availability and therapy consistency.
8 min read
Arecor CEO on FY25 Highlights: AT278 & GLP-1 Progress
Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.
4 min read
Eli Lilly Turns to AI After GLP-1 Boom for Next Growth
Eli Lilly is leveraging artificial intelligence to find its next big breakthrough after the GLP-1 boom transformed diabetes and obesity treatment. With rivals like Novo Nordisk in hot pursuit, Lilly's AI investments promise faster drug discovery and smarter clinical trials. This strategic shift could diversify revenue and bring new options to patients sooner.
6 min read
Ajanta Pharma, Sun Pharma Poised for GLP-1 Opportunity in India Market Shift
India's metabolic therapy market is shifting dramatically after semaglutide's patent expiry, slashing prices by 85-90% and unlocking demand for 75-80 million obese individuals. Ajanta Pharma gears up for generic semaglutide launch, while Sun Pharma leverages innovations for sustained growth. Analysts forecast the GLP-1 segment scaling to INR34-67 billion in 3-5 years amid rising specialist adoption.
4 min read
What to Do When Tirzepatide Stops Working: Shift to Retatrutide
If Tirzepatide worked initially but now you've hit a plateau, it's not failure—it's metabolic adaptation signaling the next phase. California Trim Clinic is leading the shift to retatrutide, a triple-pathway therapy targeting energy expenditure for sustained results. Patients are moving beyond plateaus with physician-guided care.
4 min read
Expanding Access to GLP-1 Weight-Loss Meds is Essential
Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.
5 min read
Biomea Fusion Reports Positive Phase II Data for Diabetes Drug Icovamenib
Biomea Fusion has released promising Phase II data from the COVALENT-111 study, demonstrating icovamenib's ability to significantly reduce HbA1c levels in specific diabetes patient subgroups over 52 weeks. With no serious treatment-related adverse events and durable effects nine months post-dosing, this oral menin inhibitor could offer new options for metabolic disease management. Investors note positive stock momentum amid upcoming trials.
5 min read
GLP-1 Discontinuation: Mixed Weight Loss Results in Real-World Study
A large real-world study from Cleveland Clinic reveals mixed outcomes after GLP-1 discontinuation: 55% of obese patients regained weight, while 45% maintained or continued losing. Many switched to alternative treatments, highlighting the need for ongoing obesity care. This data underscores gaps in long-term management and the role of nutritional support.
5 min read
Ireland's Each-Way Bet on Wegovy and Mounjaro Rivals
A spectacular backfire in Novo Nordisk's head-to-head trial against Eli Lilly's Mounjaro has widened the gap in the weight loss drug race, yet Ireland stands to gain from both giants. With billions in investments, thousands of jobs, and massive tax revenues, the Republic is placing an each-way bet on Wegovy and Mounjaro. This economic tie underscores pharma's pivotal role in Ireland's prosperity.
6 min read
Eli Lilly's Orforglipron: More Effective GLP-1 Pill for Weight Loss?
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
6 min read
Eris Lifesciences Partners Natco for Semaglutide in India
Eris Lifesciences has partnered with Natco Pharma to bring semaglutide, a key GLP-1 receptor agonist, to the Indian market for Type 2 diabetes management. With CDSCO approval secured, the launch is set for March 2026. This move strengthens Eris's diabetes portfolio amid rising diabetes cases in India.
5 min read
Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
5 min read
Brain Insulin Resistance: Driving Alzheimer's as Type 3 Diabetes
Alzheimer's disease may be more than just amyloid plaques—emerging evidence points to brain insulin resistance as a core driver, earning it the label 'Type 3 diabetes.' A recent Polish study uncovers how impaired insulin signaling starves neurons of energy and accelerates toxic protein buildup. Discover the science and potential therapies like GLP-1 agonists that could change the game.
5 min read
Rejuva Gene Therapy: One-Shot Fix for GLP-1 Weight Loss?
GLP-1 drugs like Ozempic and Wegovy have revolutionized weight loss, but high dropout rates leave many patients vulnerable. Enter Rejuva: a one-time gene therapy from Fractyl Health aiming for years of benefits without injections. We break down the science, promise, and risks.
4 min read
Wegovy Oral Tablet Lands in US, Delivering Innovative Pill-Based Solution for Weight Management
The United States now offers an additional avenue for weight reduction as Novo Nordisk introduces its Wegovy oral medication across the country. This daily tablet, featuring semaglutide, represents the initial and sole GLP-1 pill for adults, simplifying obesity management without injections. Clinical studies indicate notable weight loss, though side effects may occur.
2 min read
Tai Chi for Chronic Insomnia; World Health Organization's Recommendations on GLP-1 Therapies
This discussion covers key medical updates, including how tai chi compares to cognitive behavioral therapy for chronic insomnia in older adults, World Health Organization advice on using GLP-1 medications to combat obesity, the latest on vaccine efficacy for respiratory illnesses, and safety findings on oral corticosteroids during pregnancy. These insights highlight effective treatments and preventive measures for better health outcomes.
5 min read